Trial Profile
A Randomized, Double-Masked, Active-Controlled, Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Diabetic Macular Edema
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Jun 2022
Price :
$35
*
At a glance
- Drugs Aflibercept/nesvacumab (Primary) ; Aflibercept
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- Acronyms RUBY
- Sponsors Regeneron Pharmaceuticals
- 01 Jun 2022 Results published in the Retina
- 27 Nov 2017 According to a Regeneron Pharmaceuticals media release, results from this trial will be further analyzed and will be submitted for presentation at a future medical congress.
- 18 Oct 2017 Status changed from active, no longer recruiting to completed.